The Latest Breaking News from MHRA

Alzheimer’s treatment donanemab is not a ‘miracle drug’ – not providing it on the NHS is the right choice

There was frustration in some corners of the media when it was announced that a new drug to slow the progression of Alzheimer’s was not going to be made available on the NHS.

The Conversation · Oct 31, 2024

Alzheimer’s drug approved in the UK, but it won’t be available on the NHS – here’s why

The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.

The Conversation · Oct 28, 2024

Doctors urged to look out for weight loss jab ‘misuse’

The medicines regulator has also urged medics to warn patients of side effects.

Evening Standard · Oct 24, 2024

Donanemab – what we know about the latest Alzheimer’s drug

The drug is one of the new ‘disease modifying’ treatments for Alzheimer’s disease.

Evening Standard · Oct 23, 2024

What you need to know about lecanemab – the Alzheimer’s drug rejected for NHS use

The drug has been developed by Eisai, a Japanese pharmaceutical company, and is sold under the brand name Leqembi

The Independent UK · Aug 22, 2024

What is Lecanemab and who makes it? Alzheimer’s drug gets approval but will not be available on the NHS

NICE says drug is not cost effective and shares fears of side effects

Evening Standard · Aug 22, 2024

First drug to slow Alzheimer’s progression will not be made available on the NHS

The spending watchdog has recommended that a drug shown to slow the progression of Alzheimer’s disease should not be rolled out on the NHS.

The Independent UK · Aug 22, 2024

UK health regulator rejects lecanemab as treatment for Alzheimer’s

Decision by Nice to rule out drug being available on NHS comes despite medicines licensing body giving green light

The Guardian - UK · Aug 22, 2024

Weight-loss jab to be used to prevent other health problems

Some 17,600 people took part in the trial and were either prescribed Wegovy or a dummy drug

The Independent UK · Jul 23, 2024

UK needs Covid-style push on dementia drugs, says ex-head of vaccine taskforce

Kate Bingham says ageing population means tackling dementia must be treated as economic imperative

The Guardian - UK · Jul 12, 2024